Conference Correspondents

Trabectedin Combined with Nivolumab in Advanced STS

CTOS 2016

The combination of trabectedin and anti–PD-1 therapy may synergistically attack tumor cells and promote antitumor immunity. This pilot feasibility study was conducted to assess the safety, toxicity, and efficacy of this combination in patients with advanced soft-tissue sarcoma (STS). Each [ Read More ]